Samsung Bioepis and Biogen Announce FDA Filing Acceptance of SB11, A Proposed Biosimilar Referencing…
Samsung Bioepis Co., Ltd. and Biogen Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application for SB11, a proposed…
Read More...
Read More...